Developer site: The content shown here is test data.

MyEClinic
MyEClinic
Health Dictionary AI Health Chat Find an Online Doctor
A serene Zen garden with raked sand and smooth stones, symbolising clarity and calm

Health Dictionary

Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.

Back to skin conditions

STEEPLE bleeding criteria

Introduction

Steeple Bleeding Criteria (DO NOT EDIT)[1]

Steeple Bleeding Criteria (DO NOT EDIT)[1]

“

Safety and Efficacy Of Enoxaparin In Percutaneous Coronary Intervention Patients: An International Randomized Evaluation Major Bleeding

  • Fatal bleeding
  • Retroperitoneal, intracranial, or intraocular bleeding
  • Bleeding that causes hemodynamic compromise requiring specific treatment
  • Bleeding that requires intervention (surgical or endoscopic) or decompression of a closed space to stop or control the event
  • Clinically overt bleeding, requiring any transfusion of ≥1 U PRBC or whole blood
  • Clinically overt bleeding, causing a decrease in hemoglobin of ≥3 g/dL (or, if hemoglobin level is not available, a decrease in hematocrit of ≥10%)

Minor

  • Gross hematuria not associated with trauma (eg, from instrumentation)
  • Epistaxis that is prolonged, is repeated, or requires plugging or intervention
  • Gastrointestinal hemorrhage
  • Hemoptysis
  • Subconjunctival hemorrhage
  • Hematoma >5 cm or leading to prolonged or new hospitalization
  • Clinically overt bleeding, causing a decrease in hemoglobin of 2 to 3 g/dL
  • Uncontrolled bleeding requiring protamine sulfate administration
 ”
References

References

  1. ↑ Stone GW, Midei M, Newman W, Sanz M, Hermiller JB, Williams J; et al. (2009). “Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial”. Circulation. 119 (5): 680–6. doi:10.1161/CIRCULATIONAHA.108.803528. PMID 19171853.

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]